Results 91 to 100 of about 39,918 (251)

Percutaneous Left Atrial Appendage Occlusion for Atrial Fibrillation in Cardiac Amyloidosis

Journal of Arrhythmia, Volume 42, Issue 1, February 2026.
Left atrial appendage occlusion‐related outcomes in patients with amyloid cardiomyopathy. ABSTRACT Background Cardiac amyloidosis (CA) is frequently complicated by atrial fibrillation (AF), yet outcomes after left atrial appendage occlusion (LAAO) in this population remain poorly defined.
Abdul Hakim Almakadma, Ramzi Ibrahim, Hoang Nhat Pham, Eiad Habib, Ahmed K. Mahmoud, Kamal Awad, Mayurkumar D. Bhakta, Eric H. Yang, Hicham Z. El Masry, Chadi Ayoub, Reza Arsanjani   +10 more
wiley   +1 more source

Cost–effectiveness and budget impact analysis of switching from apixaban to rivaroxaban treatment among patients with nonvalvular atrial fibrillation in a German healthcare setting

Journal of Comparative Effectiveness Research
Aim: Direct oral anticoagulant (DOAC) switching often occurs in patients with nonvalvular atrial fibrillation (NVAF) formedical and nonmedical reasons. Limited data describe the economic consequences of DOAC switching in patients with NVAF.
Rupesh Subash, Thomas Strakosch, Michelle Zhang, Melissa Hagan, Elke Dworatzek, Agnes Kisser, Vasileios Vasilopoulos, Chloe Salter, Carissa Dickerso, Ewa Stawowczyk   +9 more
doaj   +1 more source

High Rates of Defect Closure After Resection of Large Nonpedunculated Colorectal Lesions Using a Through‐The‐Scope Clip With Anchor Prongs

United European Gastroenterology Journal, Volume 14, Issue 1, February 2026.
ABSTRACT Background Prophylactic complete closure of mucosal defects after resection of gastrointestinal lesions is key to reducing delayed bleeding, but complete closure for large defects can be challenging with conventional through‐the‐scope clips (TTSC).
Daniel von Renteln, Douglas K. Rex, Heiko Pohl, Nikhil A. Kumta, Shannon Chan, Marvin Ryou, Zaheer Nabi, Ping Hong Zhou, Haruhiro Inoue, Joyce A. Peetermans, Matthew J. Rousseau, Jeffrey D. Mosko   +11 more
wiley   +1 more source

Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human blood.

PLoS ONE, 2013
Apixaban is a new oral anticoagulant with a specific inhibitory action on FXa. No information is available on the reversal of the antihemostatic action of apixaban in experimental or clinical settings.
Gines Escolar, Victor Fernandez-Gallego, Eduardo Arellano-Rodrigo, Jaume Roquer, Joan Carles Reverter, Victoria Veronica Sanz, Patricia Molina, Irene Lopez-Vilchez, Maribel Diaz-Ricart, Ana Maria Galan   +9 more
doaj   +1 more source

Role of new anticoagulants for the prevention of venous thromboembolism after major orthopaedic surgery and in hospitalised acutely ill medical patients. [PDF]

, 2012
SummaryAnticoagulation therapy for the prevention of venous thromboembolic events is indicated in patients after major orthopaedic surgery and in hospitalised acutely ill medical patients, who have a high or moderate risk of venous thromboembolism (VTE),
Ageno W, Spyropoulos AC, Turpie AG
core   +1 more source

The incidence of serious complications after selective laser trabeculoplasty

Acta Ophthalmologica, Volume 104, Issue 1, Page 106-113, February 2026.
Abstract Purpose To evaluate the incidence of serious complications after selective laser trabeculoplasty (SLT). Methods All patients who underwent SLT at the Department of Ophthalmology, Helsinki University Hospital, were eligible for the study from 1 January 2012 to 31 December 2018.
Eeva S. Ojanen, Joni A. Turunen, Mika Harju   +2 more
wiley   +1 more source

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban

Clinical Pharmacology: Advances and Applications, 2014
Charles Frost,1 Yan Song,1 Yu Chen Barrett,1 Jessie Wang,2 Janice Pursley,3 Rebecca A Boyd,4 Frank LaCreta1 1Exploratory Clinical and Translational Research, 2Exploratory Development Global Biometric Sciences, 3Analytical and Bioanalytical Development ...
Frost C, Song Y, Barrett YC, Wang J, Pursley J, Boyd RA, LaCreta F   +6 more
doaj  

Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation -a look beyond the excellent results [PDF]

, 2012
In this overview we address the three phase III studies that compared new oral anticoagulants (dabigatran, rivaroxaban and apixaban) with warfarin in the setting of stroke prevention in atrial fibrillation.
Crippa, L, Falanga, A, Finazzi, G, Manotti, C., Marongiu, F, Moia, M, Palareti, G, Pengo, V, Poli, D, Policarpo, D, SIRAGUSA, Sergio, TESTA, Silvia, Tiraferri, E, Tosetto, A, Tripodi, A   +14 more
core   +1 more source

Relation of the stress hyperglycaemia ratio to residual risk in anticoagulated patients with atrial fibrillation: A report from the prospective Murcia AF Project III cohort

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1431-1442, February 2026.
Abstract Introduction Atrial fibrillation (AF) carries residual thromboembolic and cardiovascular risk despite oral anticoagulation (OAC). The stress hyperglycaemia ratio (SHR), derived from admission glucose and glycated haemoglobin (HbA1c), integrates information on both acute glycaemic fluctuations and chronic glycaemic burden.
Eva Soler‐Espejo, Yang Chen, José Miguel Rivera‐Caravaca, José Antonio Sánchez‐Salas, María Asunción Esteve‐Pastor, Francisco Marín, Vanessa Roldán, Gregory Y. H. Lip   +7 more
wiley   +1 more source

Acute severe renal failure in a patient receiving apixaban: a case report

Italian Journal of Medicine
Because there is little clinical experience with apixaban in patients with severe renal impairment and non-valvular atrial fibrillation, the European Medicines Agency does not advise using it to prevent strokes in these patients.
Attilia Maria Pizzini, Chiara Fantoni, Stefania Zaccaroni, Mauro Silingardi   +3 more
doaj   +1 more source